GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) will report fourth quarter and full year 2025 financial results after market close on Thursday, Feb. 19, 2026.
Management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress. According to the company, a live webcast and recorded replay will be available at the investor relations site and open to all.
Positive
- None.
Negative
- None.
News Market Reaction – GRAL
In the trading session that priced this news, GRAL gained 1.57%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | PMA submission | Positive | -3.1% | Filed final PMA module for Galleri multi-cancer early detection test. |
| Dec 15 | Conference presentation | Neutral | -4.4% | Announced management presentation at J.P. Morgan Healthcare Conference. |
| Dec 01 | Inducement grants | Neutral | -0.9% | Granted 21,570 RSUs to 21 non-executive employees under inducement plan. |
| Nov 18 | Conference presentation | Neutral | -4.1% | Planned presentation at Piper Sandler 37th Annual Healthcare Conference. |
| Nov 12 | Quarterly earnings | Positive | +1.6% | Reported Q3 2025 revenue growth, Galleri expansion, financing, and strong cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative or muted price reactions, even around conferences and regulatory milestones, with only the last earnings report showing a positive move.
Over the last few months, GRAIL reported multiple corporate and regulatory milestones. On Nov. 12, 2025, Q3 2025 results showed revenue of $36.2M, U.S. Galleri revenue of $32.6M, and a net loss of $89.0M, alongside a ~$325M private placement, a planned $110M Samsung investment, and cash above $850M. Subsequent updates included conference presentations, inducement grants, and a key PMA submission for Galleri on Jan. 29, 2026, which drew a negative price reaction despite its importance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fourth Quarter and Full Year 2025 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q4-financial-results-2025.open-exchange.net/
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-302688442.html
SOURCE GRAIL, Inc.